newswire, breaking biotechnology and pharma news

Tuesday, February 28, 2012

Biopharmaceutical Stock Alimera Sciences (NASDAQ:ALIM) Continues Yesterday's Gains; Up Over 70% on News on ILUVIEN

New York, New York – February 28, 2012 -, an investor research portal specializing in sector research including biotech and pharma stocks, issues a trading alert update for Alimera Sciences, Inc. (NasdaqGM: ALIM), following up on yesterday’s gains, with a monster run in the stock today, moving up another 70% on over 3.6 Million shares in morning trading.

The Company reported today on the positive outcome of the Decentralized Procedure (DCP) for ILUVIEN(R) in Europe. The announcement follows the issuance of the Final Assessment Report from the Reference Member State (RMS), the Medicines and Healthcare products Regulatory Agency of the United Kingdom (MHRA), and the agreement of all the Concerned Member States (CMS) that ILUVIEN is approvable.

ILUVIEN is Alimera's sustained release intravitreal implant that releases sub-microgram levels of fluocinolone acetonide (FAc) for up to 36 months for the treatment of chronic Diabetic Macular Edema.

According to the Company:

ILUVIEN(R) expected to be the first sustained release pharmaceutical in the European Union to treat diabetic macular edema (DME)
ILUVIEN expected to be indicated for chronic DME considered insufficiently responsive to available therapies Newswire

Alimera Sciences, Inc., (NASDAQ:ALIM) based in Alpharetta, Georgia, is a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals. Presently Alimera is focused on diseases affecting the back of the eye, or retina. Its advanced product candidate, ILUVIEN, is an intravitreal insert containing fluocinolone acetonide (FAc), a non-proprietary corticosteroid with demonstrated efficacy in the treatment of ocular disease. ILUVIEN is in development for the treatment of DME, a disease of the retina that affects individuals with diabetes and can lead to severe vision loss and blindness.

About is a leader in investor stock research by sector. Sectors we cover include; cleantech and renewable energy stocks, biotech stocks, mining and gold stocks, energy stocks, water, tech, defense stocks, nanotech, agriculture and gaming.

Sign up for the free investor news and stock alerts Resources/Newsletter.asp

Research biotech stocks at the Biotech stocks Directory: BIS/Stock_List.asp

Become an Member

Follow on Twitter!/Investorideas

Follow on Facebook

Disclaimer/ Disclosure : The is a third party publisher of news and research Our sites do not make recommendations, but offer information portals to research news, articles, stock lists and recent research. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. This site is currently compensated by featured companies, news submissions and online advertising.

BC Residents and Investor Disclaimer: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info:

800-665-0411 - Source -

No comments:

Post a Comment